INTRODUCTION
The acquired immune deficiency syndrome (AIDS) results from destruction of a subset of cells (helper T-cells) which regulate the cell -mediated immune system. The causative agent was found to be an RNA retrovirus designated human immunodeficiency virus (HIV). Infection with this agent may result in only partial damage of the immune system and patients may, therefore, remain completely asympotamic. However, approximately 30% eventually develop the complete immunodeficiency syndrome. While virtually all subjects (>95 %) who have encountered the virus develop antibodies and became HIV antibody -positive, there are as yet no methods of predicting which individuals will progress to the state of profound immunodeficiency. Before the causative agent of AIDS was discovered, infective blood products were accidentally used to treat patients with bleeding disorders, including haemophilia, and many haemophiliacs are now HIV antibody -positive.I We studied these patients to determine whether in vivo testing of the cellmediated immune system could identify those who had been exposed to the HIV agent. Some workers have shown that haemophiliacs, whether HIV antibodypositive or -negative, exhibit impaired cell -mediated immune response to a specific challenge with a single antigen not previously encountered,2 although this type of testing has a number of disadvantages.3 Assessment of in vivo reactivity of the cell -mediated immune system to multiple antigens, using delayed cutaneous hypersensitivity (DCH), overcomes many of these disadvantages4 and Royal Victoria Hospital, Belfast.
The Ulster Medical Journal also provides information regarding the recall of immune response to antigens previously encountered by individuals as a result of infection and/or vaccination programmes. The Multitest CMI system5 was used to study 20 haemophiliac patients, 10 of whom were HIV antibody -positive and 10 antibody negative and 75 healthy males of similar age range.
MATERIALS AND METHODS

Study population
Twenty haemophiliac patients, age range 19 -64 years (mean 31 years) were tested using the Multitest CMI system. Nineteen patients were suffering from Haemophilia A, while one patient had Haemophilia B (Christmas disease). All patients were asymptomatic at the time of study with none displaying any clinical evidence of immunodeficiency. The testing was performed by a single investigator (RA Mcl) to avoid observer error; the HIV antibody status and T lymphocyte subsets results were determined independently. Results were compared with 75 healthy males, age range 19-65 years (mean 36 years) who were randomly selected from the general population. Persons with concurrent or recent illness were excluded as were any subjects taking drug therapy known to cause immunosuppression. Written informed consent was obtained from all subjects.
Multitest CMI and scoring system The test system consists of a plastic disposable multiple puncture device capable of simultaneously applying eight test materials. 
RESULTS
For the control population, the total inflammatory response ranged from 0-33mm with a median of 15mm. In haemophiliac patients, the range was 0-14mm with a median of 3mm. This was statistically significant at the 0.1 % level. The number of positive responses to the antigens tested also showed a significant reduction in the haemophiliacs with a median value of 2 in this group compared with 3 for the control population; this again was significant at the 0.1 % level. Overall, 99% of normal individuals reacted to one or more of the test antigens compared with 75 % of the haemophiliacs, while positive reactions to two or more antigens were found in 95 % and 50% respectively ( Table 1) . (Table I1 ). The mean number of helper T-cells in the patients positive for antibody to HIV was 675 (range 410-1180) cells/mm3 compared with a mean value of 725 (range 410-1010) cells/mm3 in the HIV antibody -negative patients. This difference was not statistically significant. All the haemophilia A patients had received cryoprecipitate and Factor VIII concentrate. The mean quantity used per patient was 51,439 units. No correlation was found between the quantity of blood product given and HIV status or degree of suppression of the cell-mediated immune response. The patient who had received the maximum quantity of Factor VIII (347,000 units) was HIV-negative with normal CMI response, while the patient with haemophilia B had received no Factor Vill or cryoprecipitate but became HIV-positive after plasma infusion. 
